Evaluating of CREATIF an Anti-coagulation Clinic (CREATIF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01349530
Recruitment Status : Completed
First Posted : May 6, 2011
Last Update Posted : January 4, 2017
Ministry of Health, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

Main objective: To evaluate the impact of CREATIF (an anticoagulation clinic in Ile de France) on monitoring and management of patients treated with VKAs compared with usual primary care.

Study hypothesis: The investigators suppose that patients will have a better quality of anticoagulation when they are managed by CREATIF than by their usual General Physicians (GP)

Condition or disease Intervention/treatment Phase
Vitamin K Antagonist Other: Evaluating of usual care Other: Evaluation of CREATIF Not Applicable

Detailed Description:

Vitamin K antagonists (VKA) are the reference of anticoagulant oral therapy concerning common diseases such as Atrial Fibrillation (AF) and Venous ThromboEmbolism (VTE). In France, approximately 600,000 patients are treated with oral anticoagulants. The treatment is monitored and adjusted on the INR. Time outside the area of target INR is directly correlated with complications (thrombotic and hemorrhagic), the time in this zone mean the effectiveness of treatment. In France, monitoring patients by GP, the percentage of the time outside the target area INR higher than their European or North American comparators. To reduce complications VKA, specialized structures for monitoring anticoagulation have emerged in recent years around the world (Netherlands, Italy, UK, Canada, and USA). The evaluations in these countries show that the percentage of time in therapeutic INR range is around 70% when the patient is monitored in anticoagulation clinic (ACC), while in France this time was measured at around 50% in surveys of usual medical care. On data obtained abroad: correlation with improved monitoring INR monitoring the ACC decreases by a factor 3-4 morbidity and mortality associated with the use of VKA and thus allows a significant reduction in hospitalizations caused by adverse drug effects and thus health care costs. In France several ACC, have emerged since 1998. Ile de France since 2004, the ACC Ile-de-France called CREATIF (Centre for Reference and Education antithrombotic Ile de France). Since its inception to date, has an active list of approximately 450 patients which monitors long-term anticoagulant treatment. The question of benefit of such a structure arises, is why this has been decided to establish a prospective randomized study to evaluate the benefit of the management of oral anticoagulant treatment by CREATIF with respect to usual medical care in terms of time in therapeutic INR range. This study of usual care, witch aims to assess two types of management of anticoagulant therapy, does not alter the type of anticoagulant therapy nor its duration. The overall medical care of patient and his care pathway will also remain unchanged. The study Randomized GP investigators, is open, prospective, is concerning primary medical care (independent central randomization). Primary care investigators are GPs managing patients treated by VKAs. They were recruited in a list of GPs working with CREATIF or through several physicians networks (North Paris Health Network, ARES 92, GP Department of Paris VII university, GP Department of Paris West). CREATIF, investigators will be usual physicians working at the anti-coagulation clinic. The aim of the study is to compare the management of patients treated with VKA by the CREATIF versus their management in primary care. Therefore, the evaluation criterion is the time in therapeutic INR range. During 6 months randomized in 2 arms: GPs versus CREATIF; During the next 6 months following the reversal mode of management is to determine the existence of prolonged benefit by one followed by CREATIF after returning to his usual medical care. The investigators will also collect the retrospective 6 months INR.A retrospective study, prospective, open and multicenter with direct individual benefit. Prospective study conducted in cross-over: anticoagulant therapy for each patient will be followed by six months CREATIF then by his GP or vice VERSA.Primary analysis: comparing the two types of monitoring parallel group after randomization: Group A in Phase 1 versus Group B in Phase 1. Primary endpoint: percentage of time in therapeutic INR range.

The main requirements of the commitment to the inclusion of GP will be:

To have a fax or email to communicate with the CREATIF To transmit its coordinated to CREATIF. Allow the TEC and the ARC to have access to medical records for establish the retrospectives records.

Support the CREATIF approach, by a letter signed sent to medical laboratories for INR values of the retrospective study.Patients treated by VKA: COUMADINE or PREVISCAN

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Evaluating of the Benefit to the Patient by Managing of His Anticoagulation Treatment by an Anti-coagulation Clinic
Study Start Date : May 2011
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2014

Arm Intervention/treatment
Experimental: Anticoagulation clinic care
Monitoring by CREATIF
Other: Evaluation of CREATIF

Active Comparator: Usual care
Monitoring by GP.
Other: Evaluating of usual care

Primary Outcome Measures :
  1. Proportion of time in the therapeutic anticoagulation range ± 0.5 INR unit. [ Time Frame: at 13 months ]

    INR goal according following areas:

    • 2 to 3 (target 2.5) / 2.5 to 3.5 (Target 3) / 3 to 4.5 (target 3.75). Anticoagulation quality was measured using percentage of time in therapeutic INR range (%TTR). Absolute difference of 10% of TTR, taking into account the published data showing a percentage of time in therapeutic INR range of about 50% with a standard deviation of around 23% in usual medical care.

Secondary Outcome Measures :
  1. Reduce accidents and iatrogenic cost, which may be related to VKA (major haemorrhage and thrombosis). [ Time Frame: at 13 months ]
  2. Number of INR prescribed by the GP during usual medical care compared with the number of INR prescribed under Monitoring by the CREATIF [ Time Frame: at 13 months ]
  3. Score of education one month before and after the formation session [ Time Frame: at 13 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


General Physicians in the city and have agreed to participate in the study by signing an undertaking.


  • Patient has not expressed its opposition to the use of data as part of research
  • Patient man or woman whose age is ≥ 18 years
  • Patients whose condition requires treatment by VKAs PREVISCAN® or COUMADINE® with an INR target in areas following: 2 to 3 (target 2.5), 2.5 to 3.5 (target 3) or 3 to 4.5 (target 3.75)
  • Patient for which the oral anticoagulant treatment had been prescribed and administered for at least 6 months
  • Patient insured under Social Security

Exclusion criteria:

-Patient treated by SINTROM®

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01349530

Service d'hématologie - Hôpital Lariboisière
Paris, France, 75010
50, rue de la Justice
Paris, France, 75020
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France
Principal Investigator: Ludovic DROUET, MD,PhD Assistance Publique - Hôpitaux de Paris

Responsible Party: Assistance Publique - Hôpitaux de Paris Identifier: NCT01349530     History of Changes
Other Study ID Numbers: K080905
2010-A00213-36 ( Other Identifier: IDRCB )
First Posted: May 6, 2011    Key Record Dates
Last Update Posted: January 4, 2017
Last Verified: December 2016

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Usual medical care
Anticoagulation by VKAs: COUMADINE® & PREVISCAN®
Anticoagulation clinic care, CREATIF